Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 5/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706975 | 0.91 | HSP90AA1 (0.35) | POLBHSP90AA1HSP90AB1GRM2HTT | |
| SCHEMBL4759295 | 0.89 | POLB (0.37) | POLBCYP19A1HSP90AA1HSP90AB1HTT | |
| SCHEMBL4705960 | 0.86 | HSP90AA1 (0.33) | POLBHSP90AA1HSP90AB1HTTL3MBTL1 | |
| SCHEMBL4708507 | 0.86 | HSP90AA1 (0.34) | POLBCYP19A1HSP90AA1HSP90AB1GRM2 | |
| SCHEMBL3669940 | 0.85 | CYP19A1 (0.48) | POLBALDH1A1CYP19A1GRM2 | |
| SCHEMBL4707683 | 0.82 | HSP90AA1 (0.35) | POLBHSP90AA1HSP90AB1HTTL3MBTL1 | |
| SCHEMBL3673183 | 0.81 | CDC7 (0.48) | GRM2NR1H2NR1H3PTGER4 | |
| SCHEMBL4295553 | 0.80 | CDC7 (0.46) | CYP19A1GRM2 | |
| SCHEMBL4707593 | 0.80 | P2RX7 (0.36) | CYP19A1HSP90AA1HSP90AB1 | |
| SCHEMBL4708592 | 0.79 | HSP90AA1 (0.33) | POLBHSP90AA1HSP90AB1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501808-B1 | TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1501808-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091227-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | POLB 4843/4885ALDH1A1 1988/4885GAA 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.